Cargando…

Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?

Detalles Bibliográficos
Autores principales:	Staessen, Jan A., Janssens, Stefan, Van de Werf, Frans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Reports Invited Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790104/ https://www.ncbi.nlm.nih.gov/pubmed/35112113 http://dx.doi.org/10.1016/j.ijcrp.2021.200100

Ejemplares similares

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

Benefit of Heart Rate Reduction in Heart Failure
por: Hasenfuss, Gerd
Publicado: (2010)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Commentary: “Lower is Better” — SPRINTing to STEPping up hypertension research? An historical perspective on hypertension trials
por: Yu, Yu-Ling, et al.
Publicado: (2021)

Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors
por: Tuttle, Katherine R.
Publicado: (2023)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

An enhanced ceramide-based approach for primary prevention of atherosclerotic events
por: Vasile, Vlad C, et al.
Publicado: (2021)

Failure to Rescue, Failure to Respond
por: Bromberger, Bianca, et al.
Publicado: (2023)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Do we really need another risk prediction rule? Yes, we do
por: Lo, Alexander X., et al.
Publicado: (2022)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Candy-plug: Failure to launch
por: Sweet, Matthew P.
Publicado: (2023)

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
por: Packer, Milton
Publicado: (2019)

Lycopene and male infertility: do we know enough?
por: Pakrashi, Tarita, et al.
Publicado: (2014)

COVID‐19 and cardiac surgery: Do outcomes differ?
por: Harky, Amer, et al.
Publicado: (2020)

SCI and VP Shunt: Do These Letters Work Together?
por: Subramanian, Tanvi, et al.
Publicado: (2020)

Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?
por: Lubsen, Jacobus
Publicado: (2000)

Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?
por: Hsia, Henry H, et al.
Publicado: (2000)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Class effect for SGLT-2 inhibitors: a tale of 9 drugs
por: Giugliano, Dario, et al.
Publicado: (2019)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Debate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?
por: Goldstein, Sidney
Publicado: (2000)

Erythrocyte metabolism, oxygen delivery, and hypertensive kidney disease
por: Limper, Ulrich, et al.
Publicado: (2020)

Sport in ischemic heart disease: Focus on primary and secondary prevention
por: Romano, Silvio, et al.
Publicado: (2023)

Post-Operative Analgesics Score, Another Tool in the Quest for a Better Pain Management
por: Peralta, Ruben, et al.
Publicado: (2023)

Liver, Heart, Death… Can This Sequence Be Broken?
por: Manka, Paul
Publicado: (2023)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis
por: Potier, Louis, et al.
Publicado: (2021)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Extended lymph node dissection for intermediate and high-risk prostate cancer: do we have all the evidence?
por: Ghazi, Ahmed
Publicado: (2015)

Do maternal anti–N‐methyl‐D‐aspartate receptor antibodies promote development of neuropsychiatric disease in children?
por: Pröbstel, Anne‐Katrin, et al.
Publicado: (2019)

Ventriculostomy Without Decompressive Suboccipital Craniectomy for a Devastating Posterior Fossa Mass Lesion: Doing “Everything” for the Family
por: Hwang, David Y.
Publicado: (2020)

How can we cure a heart “in flame”? A translational view on inflammation in heart failure
por: Hofmann, Ulrich, et al.
Publicado: (2013)

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
por: Surma, Stanisław, et al.
Publicado: (2021)

Renal failure as a complication of defunctioning ileostomy: more complexity to a complex decision-making process
por: Lederhuber, Hans
Publicado: (2023)

Molecular genetics to genomic medicine practice: at the heart of value-based delivery of healthcare
por: Eng, Charis
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lcedg5ivlnlbs8dgpffmmu740h